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DF267G mutant. The protocols described have been optimized for
maximum yield and purity with minimal puriﬁcation steps
required and the proteins subsequently used to develop a
ﬂuorescence-based assay for drug binding to the kinase, “Using the
ﬂuorescent properties of STO-609 as a tool to assist structure-
function analyses of recombinant CaMKK2” [1].
Crown Copyright & 2016 Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biochemistry, Molecular Biology
ore speciﬁc sub-
ject areaProtein expression and puriﬁcationype of data Figures, table
ow data was
acquiredCloning and recombinant expression technology, afﬁnity and size exclusion
chromatographyata format Raw, analyzed
xperimental
factorsCommon laboratory practises, when handling recombinant bacteriaxperimental
featuresE. coli protein expression, protein puriﬁcation via afﬁnity (NiNTA) chroma-
tography and size exclusion chromatographyata source
locationOslo, Norway; Heidelberg, Germanyata accessibility Data is with this articleD
Value of the data
 CaMKK2 has relevance as an important cancer drug target and its structural-functional relationship
is not fully understood yet which makes further characterization dependent on highly pure kinase
protein.
 A detailed process for expression and puriﬁcation of CaMKK2 in complex with calmodulin is
described.
 E. coli expression with subsequent afﬁnity and size exclusion chromatography ensure proper
protein purity and absence of protein aggregates.
 The data include the protocols for full-length CaMKK2, a shorter construct encompassing kinase
domain and CaM-binding domain only, as well as a full-length CaMKK2 construct with a single
mutation in the ATP-binding pocket.
 The methods and data described provide an experimental guide to further deﬁne structural and
functional aspects of CaMKK2.1. Data
We describe the cloning strategy for subsequent expression and puriﬁcation of the complex of
CaMKK2 and CaM, and in addition for CaMKK2 ‘apo’, a truncated construct including only residues
165 to 501 CaMKK2(165-501) in complex with CaM, and a single mutation construct CaMKK2
(F267G); all primers and expression vectors are listed. Protein expression in E. coli Rosetta™ II (DE3)
and the puriﬁcation steps (afﬁnity and size exclusion chromatography), including cleavage of the His-
tag, are all validated by showing corresponding chromatograms and LDS-PAGEs.
L. Gerner et al. / Data in Brief 8 (2016) 733–740 735The essential information used to generate these data are provided below in the form of
expression and puriﬁcation protocols.2. Experimental design, materials and methods
Unless otherwise speciﬁed, all chemicals and reagents were purchased from Sigma-Aldrich in at
BioUltra reagent grade.Fig. 1. Workﬂow diagram. CaMKK2-pET30-Ek/LIC and CaM-pET8a were co-transformed into E. coli Rosetta™ II (DE3) and
overexpression performed as indicated. LDS-PAGE shows samples taken before induction and 18 hours after induction;
M¼molecular weight marker. Bands corresponding to overexpressed CaMKK2 and CaM proteins are marked. The His6-tagged
full-length CaMKK2 protein (541 aa) with its kinase domain (KD) (aa 165-446), arginine-proline-rich site (RP) (aa 204-226),
autoinhibitory domain (AID) (aa 472-477), CaM binding domain (aa 475-500). The binding of CaM to CaMKK2 is Ca2þ-
dependent and consequently, CaCl2 was included throughout expression and puriﬁcation. Protein puriﬁcation was achieved as
outlined. Afﬁnity chromatography was followed by TEV-cleavage and dialysis. After a second afﬁnity chromatography step the
CaMKK2:CaM complex was subjected to size exclusion chromatography.
Table 1
The primers include pET-30/Ek-LIC speciﬁc sequences (underlined) and CaMKK2 gene sequence construct overlab in bold,
BamHI and XhoI sites (italic). Sequence for the TEV site (grey) coding for ENLYFQG. All reverse primers include a stop codon in
parentheses. Primers given for the CaMKK2 F267G mutation only describe the primers used in the quickchange kit.
Cloning
Sequence 50–30
CaMKK2 into pET-30/Ek-LIC fwd GACGACGACAAGATGGAGAATCTTTATTTTCAGGGCTCATCATGTGTCTCTAGCCAG
rev GAGGAGAAGCCCGG(TTA)CAAGAGCACTTCCTCCTCCCC
CaMKK2 into pET28a fwd GCGGATCCTCATCATGTGTCTCTAGCCAG
rev GGCCTCGAG(TCA)CAAGAGCACTTCCTCCTCCCC
CaMKK2 F269G into pET28a fwd TACATGGTGGGCGAACTGGTC
rev GACCAGTTCGCCCACCATGTA
CaMKK2 165-501 into pET28a fwd GCGGATCCTATACCCTGAAGGATGAAATTG
rev GGCCTCGAG(CTA)CTCGAATGGGTTCCCAAAGG
Sequencing
Sequence 50–30
CaMKK2-pET30-EK/LIC fwd TAATACGACTCACTATAGGG
rev CTAGTTATTGCTCAGCGG
CaMKK2-pET28a fwd TAATACGACTCACTATAGGG
rev GCTAGTTATTGCTCAGCGG
CaM -pET8a fwd CGCAAATGGGCGGTAGGCGTG
rev CAGGGTGCCGGTGATGCGGC
L. Gerner et al. / Data in Brief 8 (2016) 733–7407362.1. Cloning strategy
Previously, de Diego et al. [2] reported a method to co-purify CaM with a fragment of the CaM-
binding kinase, DAPK1 (aa 1-334). This involved the co-transformation and co-expression of His-
tagged kinase with un-tagged calmodulin (CaM). In this data, we adopted an analogous approach
(Fig. 1) and used His-tagged full-length CaMKK2 and un-tagged CaM.
Therefore, the gene sequence of the full-length CaMKK2 construct was ampliﬁed by polymerase
chain reaction (PCR) from a pCMV-Ac-GFP vector containing human CaMKK2 isoform 3 (Q96RR4-3,
KKCC2_HUMAN) (Origene). The ampliﬁed gene fragment was cloned into a pET30-Ek/LIC vector
(Novagen), hereafter be referred to as CaMKK2, using ligation-independent cloning (LIC) according to
the manufacturer's instructions. With the pET30-Ek/LIC we incorporated an additional Tobacco Etch
Virus (TEV) protease cleavage site in the forward primer (Table 1). Truncated constructs had also been
cloned into pET28a using BamHI and XhoI restriction sites. The truncated CaMKK2 construct con-
taining residues 165 to 501 (CaMKK2 (165-501)) was selected to encompass the kinase domain (aa
165-446) including the putative CaM-binding site (aa 475-500). The second construct, CaMKK2 with a
single mutation in the so-called ‘gatekeeper’ residue (F267G) of the nucleotide binding pocket, has
been mutated using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) as to
manufacturer's description using the CaMKK2-pET28a construct as a template. Human CaM (P62158,
CALM_HUMAN) cloned into pET8a with Nco I and Bam HI sites has been kindly provided by Inaki de
Diego (EMBL Hamburg). All resulting plasmids were controlled by DNA sequencing using the com-
mercial service GATC Biotech (Konstanz, Germany). All primers used in this study (Sigma-Aldrich and
GATC Biotech) are listed in Table 1.
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For co-expression of the CaMKK2:CaM complex, the E. coli Rosetta™ II (DE3) strain was used. This
strain is designed to enhance the expression of eukaryotic proteins, with reading frames that contain
codons rarely used by E. coli. The CaMKK2 reading frame has a high number of rare codons, parti-
cularly the codon for proline (CCC) within the N-terminal coding region of CaMKK2. The E. coli
Rosetta™ II (DE3) strain supplies tRNAs for seven rare codons on a compatible chloramphenicol-
resistant plasmid [3]. We co-transformed E. coli Rosetta™ II (DE3) with CaMKK2-pET30-Ek/LIC andFig. 2. Puriﬁcation of the CaMKK2:CaM protein complex. M¼molecular weight marker. Bands corresponding to overexpressed
CaMKK2 and CaM proteins are marked with an asterisk.
L. Gerner et al. / Data in Brief 8 (2016) 733–740738CaM-pET8a constructs by heat-shock and plated them onto agar plates. The co-transformed bacteria
grow under triple antibiotic selection (ampicillin 100 μg/ml, kanamycin 25 μg/ml and chlor-
amphenicol 35 μg/ml) since the pET30-Ek/LIC vector contains an antibiotic resistance cassette against
kanamycin, and the CaM vector (pET8a) against ampicillin, and the plasmid with rare codons on E. coli
Rosetta™ II (DE3) confer chloramphenicol resistance. A 100 ml overnight culture was used to
inoculate 10 l of Luria broth (LB) medium (1% tryptone, 0.5% yeast extract (Oxoid), 0.5 % NaCl (VWR)),
supplemented with triple antibiotic selection, 5 mM CaCl2 (included throughout expression to sta-
bilise the CaMKK2:CaM complex) and 0.06% PEG 2000. The culture was left to grow at 37 °C using a
LEX™-48 bioreactor (Harbinger Biotechnology and Engineering) to an optical density (OD) measured
at 600 nm (OD600 nm) of 1.0-2.0 at which point the culture was cooled to 18 °C. Protein expression was
induced at 18 °C by adding 0.6 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) (Biosynth), over
expression was left to continue overnight (16 h). The level of over expressed construct was assessed
by lithium dodecyl sulphate–polyacrylamide gel electrophoresis (LDS-PAGE) (Fig. 1). The prominent
bands at around 65 kDa and 17 kDa correspond to the molecular weights of CaMKK2 and CaM,
respectively.
The multi-step puriﬁcation of the CaMKK2:CaM complex was achieved over two days. All pur-
iﬁcation steps were carried out at 4 °C. The cells were harvested by centrifugation at 20,000g for
20 min and pellets were resuspended in lysis buffer (30 mM Hepes pH 7.2, 120 mM NaCl, 6 mM CaCl2,
20 mM imidazole, 8 mM beta-mercaptoethanol, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF; Nigu
Chemie GmbH, Germany), 1 U/ml DNAse). The cells were lysed using a bead beater (Hamilton Beach,
908™; 0.1 mM glass beads) for 31 min and cellular debris was removed by centrifugation at
100,000g for 25 min. The His-tagged recombinant CaMKK2 along with un-tagged CaM was captured
on a Ni-NTA Chelating HP column (GE Healthcare) in loading buffer (30 mM Hepes pH 7.2, 120 mM
NaCl, 6 mM CaCl2, 20 mM imidazole, 8 mM beta-mercaptoethanol, 1 mM PMSF), followed by exten-
sive washing with more than 20 column volumes of loading buffer and a high salt wash step (30 mM
Hepes pH 7.2, 1 M NaCl, 6 mM CaCl2, 20 mM imidazole, 8 mM beta-mercaptoethanol, 1 mM PMSF) to
remove the high amount of contaminants present. The chromatogram (Fig. 2A left) shows the
absorbance proﬁle (blue) and the imidazole gradient (purple) from 20 to 500 mM which was applied
over 100 ml to elute the protein. Load, ﬂow-through, wash steps, and eluate fractions were collected,
separated by LDS-PAGE using precast NuPAGE 4–12 % Bis-Tris gels (LifeTechnologies) and subse-
quently stained with Coomassie (50 % EtOH, 10 % AcOH, 0.1 % Coomassie Brilliant Blue) to determine
purity. The corresponding LDS-PAGE gel (Fig. 2A right) shows equal volumes of the load, ﬂow-
through, wash and high-salt wash material. Following, there are shown twelve elution steps, corre-
sponding to 104–208 mM imidazole. Fractions corresponding to 120–228 mM imidazole (green
highlighted) were pooled and subsequently incubated with puriﬁed His-TEV protease [3] to cleave off
the N-terminal His-tag. To identify the optimal ratio, we initially digested Ni-NTA puriﬁed protein
complex of CaMKK2:CaM with His-TEV protease in different ratios. A ratio of 1 : 0.1 (protein : His-
TEV) gave sufﬁcient cleavage, indicated by a clear shift in size of His6-tagged CaMKK2 to TEV-digested
CaMKK2 (Fig. 3). This ratio was used for subsequent digests. Protein samples were further dialysed
overnight in 30 mM Hepes pH 7.2, 120 mM NaCl, 6 mM CaCl2, 8 mM beta-mercaptoethanol. Un-
cleaved CaMKK2 was removed by applying the digest a Ni-NTA column equilibrated in loading buffer,
by collecting the ﬂow through un-cleaved CaMKK2:CaM would stay on the column while leaving theFig. 3. His-TEV test digest. M¼molecular weight marker.
Fig. 4. Puriﬁcation of apo-CaMKK2. M¼molecular weight marker. Bands corresponding to overexpressed CaMKK2 protein are
marked with an asterisk.
L. Gerner et al. / Data in Brief 8 (2016) 733–740 739cleaved product to ﬂow through (Fig. 2B). We estimate that 4 90 % of the His-tag was removed by
this procedure (Fig. 2B, elution peak 1 and 2). The corresponding LDS-PAGE gel shows equal volumes
of the pooled protein sample before and after incubation with TEV protease. Following, there are
shown ten ﬂow through steps, corresponding to the un-tagged protein sample. The imidazole elution
peaks correspond to the His-TEV protease. Flow through fractions (green highlighted) were pooled
and concentrated using an Amicons Stirred Cells concentrator with a cut-off membrane of 30 kDa.
The puriﬁcation was ﬁnalized with a ﬁne polishing step performed on size-exclusion chromatography
(SEC), carried out in 30 mM Hepes pH 7.2, 120 mM NaCl, 6 mM CaCl2, 5 mM dithiothreitol (DTT) by
L. Gerner et al. / Data in Brief 8 (2016) 733–740740injecting the protein in 0.5 ml increments into a Superdex 200 10/300 GL column (GE Healthcare)
using a 10 ml superloop (GE healthcare). The spectral trace from the column (Fig. 2C, blue) revealed a
particularly prominent peak in the void volume which did not correspond to visible protein on the
corresponding LDS-PAGE gel (Fig. 2C) on which all main peaks between 7 and 25 ml were validated.
The lower molecular band at 50 kDa that elutes after CaMKK2:CaM we expect is remaining TEV
protease, separated at this point. Importantly, the CaMKK2:CaM complex co-eluted visibly on the gel
in the highlighted fractions (green) corresponding to a molecular weight of 78 kDa and indicating a
1 : 1 complex. These fractions were pooled and concentrated rated in Vivaspin 20 concentrators
(Satorius stedim biotech, 10 kDa MWCO) for further validation and characterisation studies. Protein
concentration was determined with the Nanodrop2000 (ThermoFisher scientiﬁc) using calculated
extinction coefﬁcients (Expasy/ProtParam).
2.3. Expression and puriﬁcation of CaMKK2, CaMKK2(165-501):CaM complex, and CaMKK2 F267G
An equivalent expression and puriﬁcation was performed for CaMKK2 (without CaM) (Fig. 4).
Notably, the spectral trace from the column (Fig. 4C, blue) revealed an almost identical proﬁle
compared to CaMKK2:CaM (purple) which may reﬂect that CaMKK2 in solution is more ﬂexible and
thus mimic protein of larger hydrodynamic volume, while the CaMKK2:CaM complex form a more
compact spherical hetero dimer. Again, the prominent peak in the void volume did not correspond to
visible protein on the corresponding LDS-PAGE gel on which all main peaks between 8 and 25 ml
were validated. Importantly, CaMKK2 eluted visibly on the gel in the highlighted fractions (green)
corresponding to a molecular weight of 65 kDa. Thus making further separation of CaMKK2 and
CaMKK2:CaM complex inefﬁcient via SEC, the single proﬁles do however show that the proteins seem
monodisperse in solution. The unbound CaM was untagged and would have eluted earlier in the
puriﬁcation process.Funding sources
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